Showing 8181-8190 of 8879 results for "".
- Indiana Becomes First 'SUNucated' State in 2018https://practicaldermatology.com/news/indiana-becomes-first-sunucated-state-in-2018/2457826/The Indiana Academy of Dermatology (IAD), with a grant from the American Society for Dermatologic Surgery Association (ASDSA), helped successfully pass legislation to ensure students are protected from the dangers of UV rays while
- Sun Pharma: FDA Approves Ilumya for Adult Psoriasishttps://practicaldermatology.com/news/sun-pharma-fda-approves-ilumya-for-adult-psoriasis/2457831/The FDA has approved Ilumya™ (tildrakizumab-asmn) from Sun Pharma for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Ilumya selectively binds to the p19 subunit of IL-23 a
- Proscia Inks Agreement to Bring Deep-Learning Technology to Dermatopathologyhttps://practicaldermatology.com/news/proscia-inks-agreement-to-bring-deep-learning-technology-to-dermatopathology/2457832/Proscia Inc., creators of AI-powered digital pathology software, signed a first-of-its-kind agreement with one of the largest dermatopathology labs in the country. This agreement provides Proscia with exclusive access to pathology slides and expert pathologist ground-truth data for an arr
- First Patient Dosed in Proof-of-Concept Trial of Topical by Design JAK Inhibitor SNA-125 for Atopic Dermatitishttps://practicaldermatology.com/news/first-patient-dosed-in-proof-of-concept-trial-of-topical-by-design-jak-inhibitor-sna-125-for-atopic-dermatitis/2457839/The first patient has been dosed in Sienna Biopharmaceuticals, Inc.'s Phase 1/2 proof-of-concept clinical trial of topical product candidate SNA-125 in the treatment of atopic dermatitis and the associated pruritus. SNA-125 is designed to inhibit Janus kinase 3, or JAK3, and tropomyosin recep
- Medimetriks Divests Xepi Cream to Cutanea Life Scienceshttps://practicaldermatology.com/news/medimetriks-divests-xepi-cream-to-cutanea-life-sciences/2457850/Medimetriks Pharmaceuticals, Inc. divested exclusive US rights for Xepi (ozenoxacin cream) 1% to Cutanea Life Sciences, Inc. for up to $30 million, with $29 million to be paid in 2018, plus the assumption of $5 mil
- Early Botox Improves Final Appearance in 'Split-Scar' Studyhttps://practicaldermatology.com/news/early-botox-treatment-improves-final-appearance-in-split-scar-study/2457856/Early injections of botulinum toxin A can improve the final appearance of surgical scars, according to a study in the March issue of Plastic
- Vit D Levels Elevated in Acnehttps://practicaldermatology.com/news/vit-d-levels-higher-in-acne/2457867/Levels of vitamin D are higher in acne patients, compared to age/sex matched controls. Researchers found a significant inverse relation between level of 25 hydroxy vitamin D and severity of acne vulgaris before treatment, according to a study in Journal of Cosmetic Dermatology.
- MainPointe Pharmaceuticals to Purchase and License Mission's Consumer Productshttps://practicaldermatology.com/news/mainpointe-pharmaceuticals-to-purchase-and-license-missions-consumer-products/2457868/Mission Pharmacal Company has recently divested several consumer products to MainPointe Pharmaceuticals, LLC. In addition, the marketing rights of additional consumer products have been licensed by Mission to MainPointe. As part of these transactions, the companies have also entered into a renewa
- Asthma and Allergy Foundation Study Shows High Prevalence and QoL Impact for Adults with Atopic Dermatitishttps://practicaldermatology.com/news/asthma-and-allergy-foundation-study-shows-high-prevalence-and-qol-impact-for-adults-with-atopic-dermatitis/2457872/The Asthma and Allergy Foundation of America (AAFA) shared data demonstrating the high rate of prevalence of atopic dermatitis (AD) in the US adult population and a greater impact on health-related quality of life and mental health symptoms, such as depression and anxiety, for patients with moder
- FDA Grants Priority Review for Genentech's Rituxan for Pemphigus Vulgarishttps://practicaldermatology.com/news/fda-grants-priority-review-for-genentechs-rituxan-for-pemphigus-vulgaris/2457883/The FDA has accepted Genentech’s Supplemental Biologics License Application (sBLA) and granted Priority Review for the use of Rituxan (rituximab) for the treatment of pemphigus vulgaris (PV). Genentech is a member of the Roche Group. <